EP1066380B1
(en)
*
|
1998-05-19 |
2001-11-14 |
Avidex Ltd |
Soluble t cell receptor
|
EP1118661A1
(en)
*
|
2000-01-13 |
2001-07-25 |
Het Nederlands Kanker Instituut |
T cell receptor libraries
|
WO2001090747A2
(en)
*
|
2000-05-25 |
2001-11-29 |
Sunol Molecular Corporation |
Modulation of t-cell receptor interactions
|
MXPA04001974A
(es)
|
2001-08-31 |
2004-07-16 |
Avidex Ltd |
Receptor de celula t soluble.
|
EP1435776A4
(en)
|
2001-09-24 |
2006-01-25 |
Univ Pittsburgh |
VACCINE AGAINST CANCER AND DIAGNOSTIC PROCEDURE AND REAGENTS
|
US8623822B2
(en)
|
2002-03-01 |
2014-01-07 |
Bracco Suisse Sa |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
US7261876B2
(en)
|
2002-03-01 |
2007-08-28 |
Bracco International Bv |
Multivalent constructs for therapeutic and diagnostic applications
|
US7794693B2
(en)
*
|
2002-03-01 |
2010-09-14 |
Bracco International B.V. |
Targeting vector-phospholipid conjugates
|
SI1482987T1
(sl)
*
|
2002-03-01 |
2014-12-31 |
Bracco Suisse Sa |
Večvalentni konstrukti za terapevtske in diagnostične aplikacije
|
US7211240B2
(en)
*
|
2002-03-01 |
2007-05-01 |
Bracco International B.V. |
Multivalent constructs for therapeutic and diagnostic applications
|
US20050100963A1
(en)
|
2002-03-01 |
2005-05-12 |
Dyax Corporation |
KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
|
EP2292638A3
(en)
|
2002-09-27 |
2011-03-23 |
Ludwig Institute For Cancer Research |
MAGE-C2 antigenic peptides and uses thereof
|
CA2501870C
(en)
*
|
2002-10-09 |
2013-07-02 |
Avidex Limited |
Single chain recombinant t cell receptors
|
NZ570811A
(en)
|
2002-11-09 |
2009-11-27 |
Immunocore Ltd |
T cell receptor display
|
GB0227351D0
(en)
*
|
2002-11-22 |
2002-12-31 |
Isis Innovation |
Soluble T-cell receptors
|
EP1567553A2
(en)
*
|
2002-12-03 |
2005-08-31 |
Avidex Ltd. |
Complexes of receptors
|
GB0304068D0
(en)
*
|
2003-02-22 |
2003-03-26 |
Avidex Ltd |
Substances
|
EP2338509B1
(en)
|
2003-06-27 |
2014-06-18 |
International Institute of Cancer Immunology, Inc. |
Method of selecting patients suitable for WT1 vaccine
|
AU2004289316B2
(en)
*
|
2003-11-10 |
2011-03-31 |
Altor Bioscience Corporation |
Soluble TCR molecules and methods of use
|
US9090673B2
(en)
|
2003-12-12 |
2015-07-28 |
City Of Hope |
Synthetic conjugate of CpG DNA and T-help/CTL peptide
|
US20060014941A1
(en)
*
|
2003-12-22 |
2006-01-19 |
University Of Tennessee Research Foundation, Inc. |
Isolated T lymphocyte receptors specific for human autoantigens complexed with human MHC molecules and methods of making and using same
|
GB0411125D0
(en)
*
|
2004-05-19 |
2004-06-23 |
Avidex Ltd |
Method of improving T-cell receptors
|
WO2007044033A2
(en)
|
2004-12-07 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
|
GB0427585D0
(en)
*
|
2004-12-16 |
2005-01-19 |
Avidex Ltd |
Assay
|
ES2599010T3
(es)
*
|
2005-04-01 |
2017-01-31 |
Immunocore Ltd. |
Receptores de linfocitos T con alta afinidad por el VIH
|
EP1888634A2
(en)
|
2005-05-13 |
2008-02-20 |
Oxford Biomedica (UK) Limited |
Mhc class i and ii peptide antigens derived from tumour antigen 5t4
|
GB0510627D0
(en)
|
2005-05-25 |
2005-06-29 |
Avidex Ltd |
Polypeptides
|
EP2463307A1
(en)
*
|
2005-08-31 |
2012-06-13 |
CBIO Limited |
Modified chaperonin 10
|
WO2007085266A1
(en)
*
|
2006-01-30 |
2007-08-02 |
Dako Denmark A/S |
High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
|
JP2009536922A
(ja)
*
|
2006-04-05 |
2009-10-22 |
ザ ジェネラル ホスピタル コーポレイション |
ウイルスに特異的な可溶性t細胞受容体組成物
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
JP5484041B2
(ja)
*
|
2007-02-23 |
2014-05-07 |
学校法人関西学院 |
蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
|
EP2857508A3
(en)
|
2007-03-05 |
2015-04-15 |
International Institute of Cancer Immunology, Inc. |
Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene, and use of them
|
AU2013206501B2
(en)
*
|
2007-03-05 |
2016-05-19 |
International Institute Of Cancer Immunology, Inc. |
Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them
|
WO2008116468A2
(en)
|
2007-03-26 |
2008-10-02 |
Dako Denmark A/S |
Mhc peptide complexes and uses thereof in infectious diseases
|
KR100877480B1
(ko)
*
|
2007-06-08 |
2009-01-07 |
왕성호 |
숫자 기억 게임 방법
|
EP3620465A1
(en)
|
2007-07-03 |
2020-03-11 |
Dako Denmark A/S |
Improved methods for generation, labeling and use of mhc multimers
|
EP2197908A2
(en)
|
2007-09-27 |
2010-06-23 |
Dako Denmark A/S |
Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
|
US10968269B1
(en)
|
2008-02-28 |
2021-04-06 |
Agilent Technologies, Inc. |
MHC multimers in borrelia diagnostics and disease
|
WO2010009735A2
(en)
|
2008-07-23 |
2010-01-28 |
Dako Denmark A/S |
Combinatorial analysis and repair
|
WO2010011994A2
(en)
|
2008-07-25 |
2010-01-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Polypeptides and uses thereof
|
GB0817244D0
(en)
|
2008-09-20 |
2008-10-29 |
Univ Cardiff |
Use of a protein kinase inhibitor to detect immune cells, such as T cells
|
US10369204B2
(en)
|
2008-10-02 |
2019-08-06 |
Dako Denmark A/S |
Molecular vaccines for infectious disease
|
GB0908613D0
(en)
*
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
WO2010151688A2
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Capture purification processes for proteins expressed in a non-mammalian system
|
GB0911566D0
(en)
*
|
2009-07-03 |
2009-08-12 |
Immunocore Ltd |
T cell receptors
|
CA2777053A1
(en)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Human single-chain t cell receptors
|
GB201002730D0
(en)
*
|
2010-02-18 |
2010-04-07 |
Uni I Oslo |
Product
|
EP3150750B1
(en)
|
2011-04-08 |
2018-12-26 |
Prognosys Biosciences, Inc. |
Peptide constructs and assay systems
|
EP2746393A4
(en)
|
2011-06-28 |
2015-06-10 |
Int Inst Cancer Immunology Inc |
RECEPTOR GENE FOR A SPECIFIC LYMPHOCYTE OF A CANCER PEPTIDE ANTIGEN
|
ES2659217T3
(es)
|
2012-03-28 |
2018-03-14 |
Gadeta B.V. |
Intercambio combinatorio de cadena receptora de célula T gamma 9 delta 2
|
SG10201700442QA
(en)
|
2012-07-27 |
2017-03-30 |
Univ Illinois |
Engineering t-cell receptors
|
AU2013308409A1
(en)
|
2012-08-31 |
2015-03-26 |
University Of Birmingham |
Target peptides for immunotherapy and diagnostics
|
WO2014039675A2
(en)
|
2012-09-05 |
2014-03-13 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
US20160000893A1
(en)
|
2012-12-13 |
2016-01-07 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
GB201223172D0
(en)
|
2012-12-21 |
2013-02-06 |
Immunocore Ltd |
Method
|
EP3736573A1
(en)
*
|
2013-03-15 |
2020-11-11 |
Prognosys Biosciences, Inc. |
Methods for detecting peptide/mhc/tcr binding
|
TR201908404T4
(tr)
|
2013-11-22 |
2019-07-22 |
Hutchinson Fred Cancer Res |
İşlenmiş yüksek afinite insan t hücresi reseptörleri.
|
WO2015091823A1
(en)
*
|
2013-12-19 |
2015-06-25 |
Friedrich-Alexander Universität Erlangen-Nürnberg |
Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
|
SG11201607181WA
(en)
|
2014-03-14 |
2016-09-29 |
Immunocore Ltd |
Tcr libraries
|
US10654908B2
(en)
|
2014-04-15 |
2020-05-19 |
University Of Virginia Patent Foundation |
Isolated T cell receptors and methods of use therefor
|
GB201409558D0
(en)
*
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
CN106279404A
(zh)
*
|
2015-05-20 |
2017-01-04 |
广州市香雪制药股份有限公司 |
一种可溶且稳定的异质二聚tcr
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
GB201514875D0
(en)
*
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Receptor
|
EP3347374A1
(en)
|
2015-09-09 |
2018-07-18 |
Immune Design Corp. |
Ny-eso-1 specific tcrs and methods of use thereof
|
GB201516272D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516274D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516275D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516277D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR libraries
|
GB201516270D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516265D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
GB201516269D0
(en)
|
2015-09-15 |
2015-10-28 |
Adaptimmune Ltd And Immunocore Ltd |
TCR Libraries
|
JP6895975B2
(ja)
*
|
2016-01-06 |
2021-06-30 |
ヘルス リサーチ インコーポレイテッドHealth Research, Inc. |
組換えt細胞受容体を含む組成物及びライブラリー並びに組換えt細胞受容体を使用する方法
|
AU2017206656B2
(en)
|
2016-01-10 |
2024-02-01 |
Neotx Therapeutics Ltd. |
Immunopotentiator enhanced superantigen mediated cancer immunotherapy
|
US20190161530A1
(en)
*
|
2016-04-07 |
2019-05-30 |
Bluebird Bio, Inc. |
Chimeric antigen receptor t cell compositions
|
MX2018013445A
(es)
|
2016-05-06 |
2019-09-09 |
Juno Therapeutics Inc |
Celulas diseñadas geneticamente y metodos para obtener las mismas.
|
US11827688B2
(en)
|
2016-06-02 |
2023-11-28 |
Immunocore Limited |
Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein
|
CA3026180A1
(en)
|
2016-06-10 |
2017-12-14 |
Gadeta B.V. |
Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
|
MA45491A
(fr)
*
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
US20200182884A1
(en)
|
2016-06-27 |
2020-06-11 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
EP3519433A1
(en)
|
2016-10-03 |
2019-08-07 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
MA46649A
(fr)
|
2016-10-13 |
2019-08-21 |
Juno Therapeutics Inc |
Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
|
JP2019532997A
(ja)
|
2016-11-03 |
2019-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
T細胞療法とbtk阻害剤との併用療法
|
US20190292246A1
(en)
|
2016-11-03 |
2019-09-26 |
Juno Therapeutics, Inc. |
Combination therapy of a cell based therapy and a microglia imhibitor
|
CA3045355A1
(en)
|
2016-12-03 |
2018-06-07 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
US11590167B2
(en)
|
2016-12-03 |
2023-02-28 |
Juno Therapeutic, Inc. |
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
MX2019006285A
(es)
|
2016-12-03 |
2019-12-16 |
Juno Therapeutics Inc |
Metodos para modulacion de celulas cart-t.
|
US20190350978A1
(en)
|
2016-12-05 |
2019-11-21 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
US11821027B2
(en)
|
2017-01-10 |
2023-11-21 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
MA47325A
(fr)
|
2017-01-20 |
2019-11-27 |
Juno Therapeutics Gmbh |
Conjugués de surface cellulaire et compositions cellulaires et méthodes associées
|
WO2018140427A1
(en)
|
2017-01-25 |
2018-08-02 |
Molecular Templates, Inc. |
Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
|
CN110612119A
(zh)
*
|
2017-02-07 |
2019-12-24 |
西雅图儿童医院(Dba西雅图儿童研究所) |
磷脂醚(ple)car t细胞肿瘤靶向(ctct)剂
|
WO2018148180A2
(en)
|
2017-02-07 |
2018-08-16 |
Immune Design Corp. |
Materials and methods for identifying and treating cancer patients
|
AU2018222749B2
(en)
|
2017-02-17 |
2024-04-18 |
Fred Hutchinson Cancer Center |
Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
|
CN110582287A
(zh)
|
2017-02-27 |
2019-12-17 |
朱诺治疗学股份有限公司 |
与在细胞疗法中给药有关的组合物、制品和方法
|
EP3589295A4
(en)
|
2017-02-28 |
2020-11-04 |
Endocyte, Inc. |
COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
|
EP3595440A2
(en)
|
2017-03-14 |
2020-01-22 |
Juno Therapeutics, Inc. |
Methods for cryogenic storage
|
US20230190796A1
(en)
|
2017-04-07 |
2023-06-22 |
Juno Therapeutics, Inc. |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
US11796534B2
(en)
|
2017-04-14 |
2023-10-24 |
Juno Therapeutics, Inc. |
Methods for assessing cell surface glycosylation
|
WO2018204427A1
(en)
|
2017-05-01 |
2018-11-08 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and an immunomodulatory compound
|
CN107216371B
(zh)
*
|
2017-05-27 |
2020-09-18 |
浙江师范大学 |
一种成人t细胞白血病的特异性靶向多肽及其应用
|
JP2020522489A
(ja)
|
2017-06-02 |
2020-07-30 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いる処置のための製造物品および方法
|
US11740231B2
(en)
|
2017-06-02 |
2023-08-29 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods related to toxicity associated with cell therapy
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
MX2020000900A
(es)
|
2017-07-29 |
2021-01-08 |
Juno Therapeutics Inc |
Reactivos para expandir celulas que expresan receptores recombinantes.
|
US11851678B2
(en)
|
2017-08-09 |
2023-12-26 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
CA3070575A1
(en)
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
EP3676403A1
(en)
|
2017-09-01 |
2020-07-08 |
Juno Therapeutics, Inc. |
Gene expression and assessment of risk of developing toxicity following cell therapy
|
EP3679370A1
(en)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics, Inc. |
Methods of identifying cellular attributes related to outcomes associated with cell therapy
|
SG11202002728VA
(en)
|
2017-10-03 |
2020-04-29 |
Juno Therapeutics Inc |
Hpv-specific binding molecules
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
EP3704251A2
(en)
|
2017-11-01 |
2020-09-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
US11851679B2
(en)
|
2017-11-01 |
2023-12-26 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
MX2020004240A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Proceso para generar composiciones terapeuticas de celulas modificadas.
|
EP3704229B1
(en)
|
2017-11-01 |
2023-12-20 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
BR112020008812A2
(pt)
|
2017-11-06 |
2020-10-27 |
Juno Therapeutics Inc |
combinação de terapia celular e um inibidor de gama secretase
|
WO2019090202A1
(en)
|
2017-11-06 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
GB201719169D0
(en)
|
2017-11-20 |
2018-01-03 |
Univ College Cardiff Consultants Ltd |
Novel T-cell receptor and ligand
|
WO2019109053A1
(en)
|
2017-12-01 |
2019-06-06 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
EP3720480A2
(en)
|
2017-12-08 |
2020-10-14 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
JP2021505168A
(ja)
|
2017-12-08 |
2021-02-18 |
ジュノー セラピューティクス インコーポレイテッド |
操作されたt細胞の組成物を製造するための方法
|
CN112041430A
(zh)
|
2017-12-08 |
2020-12-04 |
朱诺治疗学股份有限公司 |
用于培养细胞的无血清培养基配制品及其使用方法
|
AU2019209428A1
(en)
|
2018-01-22 |
2020-07-30 |
Endocyte, Inc. |
Methods of use for CAR T cells
|
JP7181517B2
(ja)
*
|
2018-01-23 |
2022-12-01 |
国立大学法人三重大学 |
T細胞レセプター
|
US20210069246A1
(en)
|
2018-01-31 |
2021-03-11 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
PE20201345A1
(es)
|
2018-04-05 |
2020-11-25 |
Juno Therapeutics Inc |
Receptores de celulas t, y celulas disenadas que expresan los mismos
|
EP3775238A1
(en)
|
2018-04-05 |
2021-02-17 |
Juno Therapeutics, Inc. |
Methods of producing cells expressing a recombinant receptor and related compositions
|
CA3095084A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
US20220275043A1
(en)
*
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
SG11202101130VA
(en)
|
2018-08-09 |
2021-03-30 |
Juno Therapeutics Inc |
Methods for assessing integrated nucleic acids
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
BR112021004261A2
(pt)
|
2018-09-11 |
2021-05-25 |
Juno Therapeutics Inc |
métodos para análise por espectrometria de massas de composições de células geneticamente modificadas
|
WO2020081537A1
(en)
*
|
2018-10-16 |
2020-04-23 |
Texas Tech University System |
Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
|
EA202191107A1
(ru)
|
2018-10-23 |
2021-09-17 |
Ридженерон Фармасьютикалз, Инк. |
T-клеточные рецепторы ny-eso-1 и способы их применения
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
EP3873919A1
(en)
*
|
2018-11-02 |
2021-09-08 |
University of Washington |
Orthogonal protein heterodimers
|
EP3877054B1
(en)
|
2018-11-06 |
2023-11-01 |
Juno Therapeutics, Inc. |
Process for producing genetically engineered t cells
|
CN113573719A
(zh)
|
2018-11-08 |
2021-10-29 |
朱诺治疗学股份有限公司 |
治疗和t细胞调节的方法和组合
|
EP3886894B1
(en)
|
2018-11-30 |
2024-03-13 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
|
US20220088070A1
(en)
|
2018-11-30 |
2022-03-24 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
MX2021013908A
(es)
|
2019-05-15 |
2022-03-11 |
Neotx Therapeutics Ltd |
Tratamiento para el cáncer.
|
MX2021015125A
(es)
|
2019-06-07 |
2022-04-06 |
Juno Therapeutics Inc |
Cultivo automatizado de celulas t.
|
CA3142361A1
(en)
|
2019-06-12 |
2020-12-17 |
Juno Therapeutics, Inc. |
Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
|
KR20220066892A
(ko)
|
2019-08-22 |
2022-05-24 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
|
JP2023500318A
(ja)
|
2019-10-30 |
2023-01-05 |
ジュノ セラピューティクス ゲーエムベーハー |
細胞選択および/または細胞刺激デバイスならびに使用方法
|
AU2020395318A1
(en)
|
2019-12-06 |
2022-06-09 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating B cell malignancies
|
MX2022009137A
(es)
|
2020-01-24 |
2022-10-21 |
Regeneron Pharma |
Antígeno expresado preferentemente en receptores de linfocitos t de melanoma (prame) y sus métodos de uso.
|
WO2021154887A1
(en)
|
2020-01-28 |
2021-08-05 |
Juno Therapeutics, Inc. |
Methods for t cell transduction
|
CN115484978A
(zh)
|
2020-03-05 |
2022-12-16 |
尼奥克斯医疗有限公司 |
使用免疫细胞治疗癌症的方法和组合物
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
KR20230022868A
(ko)
|
2020-05-13 |
2023-02-16 |
주노 쎄러퓨티크스 인코퍼레이티드 |
재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
|
US20210403528A1
(en)
*
|
2020-05-21 |
2021-12-30 |
University College Cardiff Consultants Ltd. |
Novel T-Cell Receptor and Ligand
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
WO2022060904A1
(en)
|
2020-09-16 |
2022-03-24 |
Obsidian Therapeutics, Inc. |
Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
|
WO2022133030A1
(en)
|
2020-12-16 |
2022-06-23 |
Juno Therapeutics, Inc. |
Combination therapy of a cell therapy and a bcl2 inhibitor
|
KR20230165771A
(ko)
|
2021-03-03 |
2023-12-05 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 요법 및 dgk 억제제의 조합
|
CN117321417A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
确定治疗性细胞组合物的效力的方法
|
WO2022212400A1
(en)
|
2021-03-29 |
2022-10-06 |
Juno Therapeutics, Inc. |
Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
WO2023283446A1
(en)
*
|
2021-07-09 |
2023-01-12 |
The Johns Hopkins University |
Method for surface expression of membrane proteins that have a cytoplasmic c-terminal tail
|
WO2023147515A1
(en)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Methods of manufacturing cellular compositions
|
WO2023213969A1
(en)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024054944A1
(en)
|
2022-09-08 |
2024-03-14 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
WO2024097642A1
(en)
|
2022-10-31 |
2024-05-10 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|